personalized, responsive service and to improve the site, we remember and store information about how you use
Congratulations! You now have unlimited access to all articles from The Medicine Maker.
Complete your profile at your earliest convenience to unlock the rest of your benefits:
relevant and personalised updates about your field
access to White Papers/product profiles
digital magazine subscription
The Medicine Maker
In February’s cover feature, find out what it takes to develop, safely deliver and commercialize a CAR T cell therapy with Kite Pharma. We ask what the Brexit transition period means for the pharma industry, and in particular, batch release; while Andrew Edwards argues that current market conditions aren’t suited to the development of antibiotics. In addition, find out how greater supply chain transparency will help address shortages, why so many drugs fail the final hurdle, and the benefits and dangers of human germline genome editing. We also sit down with Matthew Todd, Open Source Pharma founder.